About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle® molecules attractive candidates for drug development. The company is evaluating nuzafatide pevedotin (formerly BT5528), a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of Bicycle® Radioconjugates (BRCs) and imaging agents;; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, the use of Bicycle® technology to develop therapies to treat diseases in a range of therapeutic areas.
Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts, USA. For more information, visit bicycletherapeutics.com
Culture is key and all Bicycle employees actively embrace and role model our company values:
The Vice President, Biometrics will build, resource, oversee, and play a hands on role for the Biometrics organization. This leader holds ultimate accountability for clinical study designs, statistical methodologies, data analysis, and interpretation of results in close collaboration with partner functions across Clinical Development, Operations, and Regulatory Affairs.
As a key member of the Development Leadership Team, the VP provides strategic statistical input into Bicycle's drug development portfolio, representing the company in interactions with global Health Authorities (FDA, EMA, MHRA, RoW agencies) and contributing to the advancement of our oncology and radiopharmaceutical clinical pipelines. Additionally, this role supports early-stage research and translational sciences as required.
The ideal candidate possesses deep global clinical development expertise in oncology, combined with an outstanding track record of managing complex portfolios, driving innovation in applied statistical methodologies (including adaptive designs), and leading teams in a high-growth, agile biotechnology environment. Experience in Bayesian Trial design and radiopharmacology experience is preferred.
KEY RESPONSIBILITIES
We have shared the expected recruitment base pay range for this full-time position based on the anticipated location. The actual base pay will depend on several factors unique to each candidate, including skills, qualifications, experience, and the actual location of the role. At Bicycle, base pay is just one component of the total reward package. This role is also eligible for Bicycle’s discretionary annual bonus program (or sales incentive program), its comprehensive health and retirement benefit programs, and equity grants. During the hiring process, your Bicycle recruiter can share more about the Company’s total reward package.
Bicycle Therapeutics is committed to building a diverse workforce that is representative of the communities we serve. We recognize that diverse and inclusive teams build a stronger and more innovative company. Therefore, all qualified applicants will be considered for employment, and we do not discriminate on the basis of race, religion, colour, gender, sexual orientation, age, disability status, marital status, or veteran status.

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.